Till startsida
To content Read more about how we use cookies on gu.se

Publikationer 2003

Andersson H, Elgqvist J, Horvath G, Hultborn R, Jacobsson L, Jensen H, Karlsson B, Lindegren S and Palm S

Astatine-211-labeled Antibodies for Treatment of Disseminated Ovarian Cancer: An Overview of Results in an Ovarian Tumor Model.
Clinical Cancer Research, vol. 9, 3914s-3921s, september 1, 2003.

Bernhardt P, Benjegård SA, Nilsson O, Kölby L, Ahlman H and Forssell-Aronsson E

Biodistribution of 111In-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of injected amount and administration route.
Nucl Med Biol, 30:253-260, 2003.

Bernhardt P, Ahlman H, Nilsson O, Benjegård SA and Forssell-Aronsson E

Evaluation of 111In labeled somatostatin analogs for targeted therapy of somatostatin receptor positive tumors.
Cancer Biotherapy and Radiopharmaceuticals 18(2): 249-252, 2003.

Bernhardt P, Ahlman H and Forssell-Aronsson E

Model of metastatic growth valuable for radionuclide therapy.
Med Phys 30:3227-3232, 2003.

Börjesson J, Isaksson M and Mattsson S

X-ray fluorescence analysis in medical sciences: a review
Acta Diabetol(2003) 40:S39-S44

Carlsson J, Forssell-Aronsson E, Hietala S-O, Stigbrand T and Tennvall J

Tumour therapy with radionuclides – assessment of progress and problems.
Radiother Oncol 66(2):107-117, 2003.

Fredlund K, Bergman E L, Rossander-Hulthén L, Isaksson M, Almgren A and Sandberg A-S

Hydrothermal treatment and malting of barley improved zinc absotption but not calcium absorption in humans.
European Journal of Clinical Nutrition (2003)57, 1507-113

Hashemi SH, Benjegård SA, Ahlman H, Wängberg B, Forssell-Aronsson E, Billig H and Nilsson O

Expression of sstr2 in neuroendocrine tumours studied by ribonuclease protection assay related to 111In-octreotide binding.
Br J Surg 90(5):549-554, 2003.

Isaksson M, Bosaeus I, Surac Y and Alpsten M

Determination of potassium in the skeletal muscles by whole-body counting.
Acta Diabetol (2003) 40:s68-s72

Johansson KA, Mattsson S, Brahme A, Carlsson J, Zackrisson B, Turesson I, and the Swedish Cancer Society Investigation Group (including Forssell-Aronsson E)

Radiation therapy dose delivery.
Acta Oncol 42: 85-91, 2003.

Kölby L, Bernhardt P, Levin-Jakobsen AM, Wängberg B, Ahlman H, Forssell-Aronsson E and Nilsson O

Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters.
Br J Cancer 89: 1383-1388, 2003.

Ljungberg M, Stibrant Sunnerhagen K, Vikhoff-Baaz B, Starck G, Forssell-Aronsson E, Hedberg M, Ekholm S and Grimby G

31P MRS evaluation of fatigue in anterior tibial muscle in postpoliomyelitis patients and healthy volunteers.
Clin Physiol Funct Imag, 23:190-198, 2003.

Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kölby L, Schmitt J and Forssell-Aronsson E

Biodistribution and dosimetry of 177Lu-labelled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer.
Cancer Biotherapy and Radiopharmaceuticals, 18(4): 593-599, 2003.

Turesson I, Carlsson J, Brahme A, Glimelius B, Zackrisson B, Stenerlöw B, and the Swedish Cancer Society Investigation Group (including Forssell-Aronsson E and Johansson KA)

Biological response to radiation therapy.
Acta Oncol 42: 92-106, 2003.

Turesson I, Johansson KA, Mattsson S, and the Swedish Cancer Society Investigation Group (including Forssell-Aronsson E)

The potential of proton and light ion beams in radiotherapy.
Acta Oncol 42: 107-114, 2003.

Zackrisson B, Mattsson S, Kjellén E, Glimelius B, and the Swedish Cancer Society Investigation Group (including Forssell-Aronsson E and Johansson KA)

Research and development of radiation therapy in clinical routines.
Acta Oncol 42: 115-122, 2003.

Page Manager: Johan Spetz|Last update: 1/7/2013

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?